• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Interferon alpha for the treatment of advanced renal cancer.

作者信息

Ravaud Alain, Dilhuydy Marie-Sarah

机构信息

Department of Medical Oncology and Radiotherapy, Hôpital Saint-André, 1 rue Jean Burguet, 33075 Bordeaux cedex, France.

出版信息

Expert Opin Biol Ther. 2005 Jun;5(6):749-62. doi: 10.1517/14712598.5.6.749.

DOI:10.1517/14712598.5.6.749
PMID:15952906
Abstract

This paper is an overview on the place of IFN-alpha in metastatic renal cell carcinoma (MRCC). After a presentation of MRCC and the mode of action of IFN-alpha, the results of studies including IFN-alpha alone or in combination with IL-2, chemotherapy and other biological modifiers are presented. Finally, new trends for new drugs, including antiangiogenic therapies, are discussed.

摘要

相似文献

1
Interferon alpha for the treatment of advanced renal cancer.
Expert Opin Biol Ther. 2005 Jun;5(6):749-62. doi: 10.1517/14712598.5.6.749.
2
Novel investigative approaches for advanced renal cell carcinoma.晚期肾细胞癌的新型研究方法。
Semin Oncol. 2000 Apr;27(2):234-9.
3
Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma.转移性肾细胞癌随机试验对照臂的合理选择
Eur Urol. 2003 Jun;43(6):670-9. doi: 10.1016/s0302-2838(03)00105-2.
4
Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2.接受皮下注射α干扰素和皮下注射白细胞介素-2治疗的转移性肾癌长期存活者。
Cancer Biother Radiopharm. 2005 Aug;20(4):410-6. doi: 10.1089/cbr.2005.20.410.
5
Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review.联合或序贯策略以改善转移性肾细胞癌患者的预后：批判性评价。
Crit Rev Oncol Hematol. 2012 Jun;82(3):323-37. doi: 10.1016/j.critrevonc.2011.06.001. Epub 2011 Jul 5.
6
[Immunotherapy in metastatic cancer of the kidney].[免疫疗法在转移性肾癌中的应用]
Presse Med. 1995 Oct 28;24(32):1504-6.
7
Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.使用白细胞介素-2、α干扰素和5-氟尿嘧啶方案对转移性肾细胞癌进行免疫化疗。
J Urol. 1996 Jul;156(1):18-21.
8
[Immunotherapy of renal cell carcinoma: results from current phase-III-trials].[肾细胞癌的免疫疗法：当前III期试验的结果]
Aktuelle Urol. 2004 Apr;35(2):121-9. doi: 10.1055/s-2004-818414.
9
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.肾癌的免疫治疗策略——当酪氨酸激酶抑制剂不足时。
Nat Rev Clin Oncol. 2009 Aug;6(8):478-87. doi: 10.1038/nrclinonc.2009.91. Epub 2009 Jun 23.
10
[Interferon-alpha therapy in hypernephroma].[α干扰素治疗肾癌]
Wien Med Wochenschr. 1993;143(16-17):443-7.

引用本文的文献

1
The impact of cytoreductive nephrectomy on survival outcomes in patients with metastatic renal cell carcinoma receiving immunotherapy: An evidence-based analysis of comparative outcomes.细胞减灭性肾切除术对接受免疫治疗的转移性肾细胞癌患者生存结局的影响：基于证据的比较结局分析。
Front Immunol. 2023 Mar 14;14:1132466. doi: 10.3389/fimmu.2023.1132466. eCollection 2023.
2
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.一项多中心研究评估了接受免疫检查点抑制剂治疗联合或不联合细胞减灭性肾切除术的转移性肾细胞癌患者的生存情况。
Urol Oncol. 2023 Jan;41(1):51.e25-51.e31. doi: 10.1016/j.urolonc.2022.08.013. Epub 2022 Oct 26.
3
Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma.血小板衍生生长因子-A 的上调是导致肝细胞癌重新开始干扰素 α 治疗失败的原因。
BMC Cancer. 2012 Oct 1;12:439. doi: 10.1186/1471-2407-12-439.
4
Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: application for allogeneic transplantation.黑色素瘤细胞中BCL2A1限制性次要组织相容性抗原的异常表达：在同种异体移植中的应用
Int J Hematol. 2008 Jun;87(5):467-473. doi: 10.1007/s12185-008-0076-5. Epub 2008 Apr 15.